Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$13.18 +0.54 (+4.27%)
At close: Sep 30, 2026 · 4:00 PM EDT

Enanta Pharmaceuticals (ENTA) Current Deferred Revenue (2012 - 2014)

Updated

Enanta Pharmaceuticals' Current Deferred Revenue came in at $51,000 for fiscal Q2 2014 (quarter ended Mar 31, 2014), down 55.7% from $115,000 a year earlier but up 920.0% from the prior quarter.

Analysis

Enanta Pharmaceuticals (ENTA) Current Deferred Revenue (2012 - 2014) Analysis & Trends

At the end of FY2013 (ended Sep 30, 2013), Enanta Pharmaceuticals' Current Deferred Revenue was $10,000, down 41.2% from FY2012.

  • Going back by fiscal year, Current Deferred Revenue was $17,000 in FY2012.
  • The five-year range for quarterly Current Deferred Revenue is $5,000 (fiscal Q1 2014) to $115,000 (fiscal Q2 2013).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Enanta Pharmaceuticals 383.80 Mn -344.19 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 51,000.00
Dec 31, 2013 5,000.00
Sep 30, 2013 10,000.00
Mar 31, 2013 115,000.00
Sep 30, 2012 17,000.00
API Access

Enanta Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ENTA&period=max&api_key=YOUR_API_KEY